These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 15231431)
1. Dissolution characteristics of megaloporous tablets prepared with two kinds of matrix granules. Ozgüney I; Ertan G; Güneri T Farmaco; 2004 Jul; 59(7):549-55. PubMed ID: 15231431 [TBL] [Abstract][Full Text] [Related]
2. Eudragit(®) RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets. Dave VS; Fahmy RM; Bensley D; Hoag SW Drug Dev Ind Pharm; 2012 Oct; 38(10):1240-53. PubMed ID: 22257339 [TBL] [Abstract][Full Text] [Related]
3. Controlled release of a poorly water-soluble drug from hot-melt extrudates containing acrylic polymers. Zhu Y; Shah NH; Malick AW; Infeld MH; McGinity JW Drug Dev Ind Pharm; 2006 Jun; 32(5):569-83. PubMed ID: 16720412 [TBL] [Abstract][Full Text] [Related]
4. The influence of thermal treatment and type of insoluble poly(meth)acrylates on dissolution behavior of very soluble drug from hypromellose matrix tablets evaluated by multivariate data analysis. Kubova K; Peček D; Hasserová K; Doležel P; Pavelková M; Vyslouzil J; Muselík J; Vetchy D Pharm Dev Technol; 2017 Mar; 22(2):206-217. PubMed ID: 28058866 [TBL] [Abstract][Full Text] [Related]
5. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436 [TBL] [Abstract][Full Text] [Related]
6. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets. Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547 [TBL] [Abstract][Full Text] [Related]
7. Fast dispersible/slow releasing ibuprofen tablets. Fini A; Bergamante V; Ceschel GC; Ronchi C; de Moraes CA Eur J Pharm Biopharm; 2008 May; 69(1):335-41. PubMed ID: 18182280 [TBL] [Abstract][Full Text] [Related]
8. Artificial neural networks in the modeling and optimization of aspirin extended release tablets with Eudragit L 100 as matrix substance. Ibrić S; Jovanović M; Djurić Z; Parojcić J; Petrović SD; Solomun L; Stupar B AAPS PharmSciTech; 2003; 4(1):E9. PubMed ID: 12916918 [TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of ibuprofen pellets based on Eudragit RS PO and RL PO or their combination. Abbaspour MR; Sadeghi F; Garekani HA Int J Pharm; 2005 Oct; 303(1-2):88-94. PubMed ID: 16153792 [TBL] [Abstract][Full Text] [Related]
10. Sucrose esters with various hydrophilic-lipophilic properties: novel controlled release agents for oral drug delivery matrix tablets prepared by direct compaction. Chansanroj K; Betz G Acta Biomater; 2010 Aug; 6(8):3101-9. PubMed ID: 20132913 [TBL] [Abstract][Full Text] [Related]
11. The development of Eudragit® NM-based controlled-release matrix tablets. Dvořáčková K; Kalėdaitė R; Gajdziok J; Rabišková M; Bajerová M; Muselík J; Lažauskas R; Pečiūra R; Bernatonienė J Medicina (Kaunas); 2012; 48(4):192-202. PubMed ID: 22836292 [TBL] [Abstract][Full Text] [Related]
12. The effect of tablet formulation and hardness on in vitro release of cephalexin from Eudragit L100 based extended release tablets. Saravanan M; Nataraj KS; Ganesh KS Biol Pharm Bull; 2002 Apr; 25(4):541-5. PubMed ID: 11995942 [TBL] [Abstract][Full Text] [Related]
13. Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55. Sauer D; Zheng W; Coots LB; McGinity JW Eur J Pharm Biopharm; 2007 Sep; 67(2):464-75. PubMed ID: 17451929 [TBL] [Abstract][Full Text] [Related]
14. Floating and sustained-release characteristics of effervescent tablets prepared with a mixed matrix of Eudragit L-100-55 and Eudragit E PO. Bani-Jaber AK; Alkawareek MY; Al-Gousous JJ; Abu Helwa AY Chem Pharm Bull (Tokyo); 2011; 59(2):155-60. PubMed ID: 21297292 [TBL] [Abstract][Full Text] [Related]
15. Soluble filler as a dissolution profile modulator for slightly soluble drugs in matrix tablets. Dvorácková K; Rabisková M; Masteiková R; Muselík J; Krejcová K Drug Dev Ind Pharm; 2009 Aug; 35(8):930-40. PubMed ID: 19274510 [TBL] [Abstract][Full Text] [Related]
16. A comparative study of dissolution characteristics of polymeric and wax granulations of theophylline and their tablets. Uhumwangho MU; Okor RS Pak J Pharm Sci; 2008 Jul; 21(3):230-6. PubMed ID: 18614417 [TBL] [Abstract][Full Text] [Related]
17. Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets. Zaghloul AA; Faltinek J; Vaithiyalingam SR; Reddy IK; Khan MA Pharmazie; 2001 Apr; 56(4):321-4. PubMed ID: 11338673 [TBL] [Abstract][Full Text] [Related]
18. Modulation of drug release by utilizing pH-independent matrix system comprising water soluble drug verapamil hydrochloride. Baviskar D; Sharma R; Jain D Pak J Pharm Sci; 2013 Jan; 26(1):137-44. PubMed ID: 23261739 [TBL] [Abstract][Full Text] [Related]
19. Formulation development and in vitro evaluation of theophylline microcapsules. Ahmad M; Akhtar N; Murtaza G; Hussain SW Pak J Pharm Sci; 2012 Jan; 25(1):15-9. PubMed ID: 22186304 [TBL] [Abstract][Full Text] [Related]
20. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Akhgari A; Afrasiabi Garekani H; Sadeghi F; Azimaie M Int J Pharm; 2005 Nov; 305(1-2):22-30. PubMed ID: 16236475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]